-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since September this year, large-scale collections of proprietary Chinese medicines have followed one after another
.
On September 14, the Guangdong Provincial Drug Trading Center issued the "Guangdong Union Qingkailing and other 58 drug groups with volume procurement documents (draft for comments)", intending to deal with Qingkailing, compound Danshen, Xuesaitong, motherwort, etc.
58 commonly used Chinese patent medicines are purchased in quantity.
The purchasing alliance involves 7 provincial administrative regions including Guangdong, Shanxi, Henan, Hainan, Ningxia, Qinghai, and Xinjiang
.
On September 26, the Hubei Province Pharmaceutical Price and Bidding Purchasing Management Service Network also issued the "Announcement on Procurement of Proprietary Chinese Patent Medicines by the Inter-provincial Alliance of Centralized Volume Procurement (No.
1)", which clearly stated that Hubei Province will unite with 18 provinces including Hebei, Shanxi, and Inner Mongolia.
Carry out centralized procurement of Chinese patent medicines
.
In addition, Qinghai Province, Jinhua, Zhejiang, Puyang, Henan and other places have also successively carried out pilot projects for the centralized procurement of Chinese patent medicines.
Although it is not an alliance procurement, the centralized procurement objects are mainly some Chinese patent medicines with high demand and high prices.
Variety
.
In this regard, the analysis believes that with the continuous advancement of centralized procurement of Chinese patent medicines, a large number of medicines will usher in price cuts, while the market may also usher in major changes
.
It is understood that, in fact, more and more provinces and cities are currently exploring pilot projects for the centralized procurement of Chinese patent medicines, mainly because they are influenced by the promotion of national policies
.
On January 28 this year, the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized Drug Purchases" (hereinafter referred to as the "Opinions") clearly stated that "exploring the merger of different generic drugs with similar indications or functions and indications" Carrying out centralized procurement with quantity" provides basic compliance for the centralized procurement of Chinese patent medicines
.
In August, the National Medical Insurance Administration also made it clear that it will start with high-priced and large-volume varieties, scientifically and steadily promote the reform of centralized procurement of Chinese patent medicines and formula granules, and further accelerate the mass procurement of Chinese patent medicines
.
You know, centralized procurement often brings big price cuts to medicines
.
Although the centralized procurement of Chinese patent medicines does not have clear standards in terms of raw materials, processing methods, indications, grouping, scoring, mergers, etc.
, and the prices of raw materials are largely affected by emergencies such as droughts, floods, wind, frost, rain and snow, and epidemics.
The impact is generally small; however, the industry generally believes that under the dual impact of increasing prices of Chinese medicinal materials and increasing prices of centralized procurement, traditional Chinese medicine companies entering centralized procurement will also face cost control problems, and profit margins may be affected.
Influence
.
In the context of continued decline in profits and the continuous advancement of centralized procurement of Chinese patent medicines, the Chinese patent medicine market is expected to gradually enter the "shuffle" stage
.
Now that the centralized procurement of Chinese patent medicines is blooming all over the country, the whole Chinese patent medicine industry may face a reshuffle in the future, and a batch of products with a small market scale and no distinctive dosage forms or eliminated, how should relevant pharmaceutical companies respond? The industry believes that for Chinese medicine companies, they still need to seek innovation and transformation if they want to survive
.
Innovation is the inexhaustible driving force for the development of enterprises.
Only by following the law of TCM development, inheriting the essence, and keeping innovation, can pharmaceutical companies accelerate the modernization and industrialization of TCM, obtain more development opportunities, continuously enhance their competitiveness, and resist the market.
Turbulence
.
.
On September 14, the Guangdong Provincial Drug Trading Center issued the "Guangdong Union Qingkailing and other 58 drug groups with volume procurement documents (draft for comments)", intending to deal with Qingkailing, compound Danshen, Xuesaitong, motherwort, etc.
58 commonly used Chinese patent medicines are purchased in quantity.
The purchasing alliance involves 7 provincial administrative regions including Guangdong, Shanxi, Henan, Hainan, Ningxia, Qinghai, and Xinjiang
.
On September 26, the Hubei Province Pharmaceutical Price and Bidding Purchasing Management Service Network also issued the "Announcement on Procurement of Proprietary Chinese Patent Medicines by the Inter-provincial Alliance of Centralized Volume Procurement (No.
1)", which clearly stated that Hubei Province will unite with 18 provinces including Hebei, Shanxi, and Inner Mongolia.
Carry out centralized procurement of Chinese patent medicines
.
In addition, Qinghai Province, Jinhua, Zhejiang, Puyang, Henan and other places have also successively carried out pilot projects for the centralized procurement of Chinese patent medicines.
Although it is not an alliance procurement, the centralized procurement objects are mainly some Chinese patent medicines with high demand and high prices.
Variety
.
In this regard, the analysis believes that with the continuous advancement of centralized procurement of Chinese patent medicines, a large number of medicines will usher in price cuts, while the market may also usher in major changes
.
It is understood that, in fact, more and more provinces and cities are currently exploring pilot projects for the centralized procurement of Chinese patent medicines, mainly because they are influenced by the promotion of national policies
.
On January 28 this year, the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized Drug Purchases" (hereinafter referred to as the "Opinions") clearly stated that "exploring the merger of different generic drugs with similar indications or functions and indications" Carrying out centralized procurement with quantity" provides basic compliance for the centralized procurement of Chinese patent medicines
.
In August, the National Medical Insurance Administration also made it clear that it will start with high-priced and large-volume varieties, scientifically and steadily promote the reform of centralized procurement of Chinese patent medicines and formula granules, and further accelerate the mass procurement of Chinese patent medicines
.
You know, centralized procurement often brings big price cuts to medicines
.
Although the centralized procurement of Chinese patent medicines does not have clear standards in terms of raw materials, processing methods, indications, grouping, scoring, mergers, etc.
, and the prices of raw materials are largely affected by emergencies such as droughts, floods, wind, frost, rain and snow, and epidemics.
The impact is generally small; however, the industry generally believes that under the dual impact of increasing prices of Chinese medicinal materials and increasing prices of centralized procurement, traditional Chinese medicine companies entering centralized procurement will also face cost control problems, and profit margins may be affected.
Influence
.
In the context of continued decline in profits and the continuous advancement of centralized procurement of Chinese patent medicines, the Chinese patent medicine market is expected to gradually enter the "shuffle" stage
.
Now that the centralized procurement of Chinese patent medicines is blooming all over the country, the whole Chinese patent medicine industry may face a reshuffle in the future, and a batch of products with a small market scale and no distinctive dosage forms or eliminated, how should relevant pharmaceutical companies respond? The industry believes that for Chinese medicine companies, they still need to seek innovation and transformation if they want to survive
.
Innovation is the inexhaustible driving force for the development of enterprises.
Only by following the law of TCM development, inheriting the essence, and keeping innovation, can pharmaceutical companies accelerate the modernization and industrialization of TCM, obtain more development opportunities, continuously enhance their competitiveness, and resist the market.
Turbulence
.
